197 related articles for article (PubMed ID: 20842129)
1. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
van Herpen CM; Mauer ME; Mesia R; Degardin M; Jelic S; Coens C; Betka J; Bernier J; Remenar E; Stewart JS; Preiss JH; van den Weyngaert D; Bottomley A; Vermorken JB;
Br J Cancer; 2010 Oct; 103(8):1173-81. PubMed ID: 20842129
[TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR;
Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Psyrri A; Fortpied C; Koutsodontis G; Avgeris M; Kroupis C; Goutas N; Menis J; Herman L; Giurgea L; Remenár É; Degardin M; Pateras IS; Langendijk JA; van Herpen CML; Awada A; Germà-Lluch JR; Kienzer HR; Licitra L; Vermorken JB
Ann Oncol; 2017 Sep; 28(9):2213-2218. PubMed ID: 28651338
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Fayette J; Fontaine-Delaruelle C; Ambrun A; Daveau C; Poupart M; Ramade A; Zrounba P; Neidhardt EM; Péron J; Diallo A; Céruse P
Oncotarget; 2016 Jun; 7(24):37297-37304. PubMed ID: 27119503
[TBL] [Abstract][Full Text] [Related]
10. Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis.
Liberato NL; Rognoni C; Rubrichi S; Quaglini S; Marchetti M; Gorlia T; Licitra L; Vermorken JB
Ann Oncol; 2012 Jul; 23(7):1825-32. PubMed ID: 22104577
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Schultz JD; Bran G; Anders C; Sadick H; Faber A; Hörmann K; Sauter A
Oncol Rep; 2010 Nov; 24(5):1213-6. PubMed ID: 20878112
[TBL] [Abstract][Full Text] [Related]
12. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
Herman LC; Chen L; Garnett A; Feldman LE; Smith B; Weichselbaum RR; Spiotto MT
Oral Oncol; 2014 Jan; 50(1):52-8. PubMed ID: 24055193
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.
Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R
Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320
[TBL] [Abstract][Full Text] [Related]
14. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
Inhestern J; Schmalenberg H; Dietz A; Rotter N; Maschmeyer G; Jungehülsing M; Grosse-Thie C; Kuhnt T; Görner M; Sudhoff H; Wittekindt C; Guntinas-Lichius O
Ann Oncol; 2017 Aug; 28(8):1917-1922. PubMed ID: 28498880
[TBL] [Abstract][Full Text] [Related]
15. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Paccagnella A; Ghi MG; Loreggian L; Buffoli A; Koussis H; Mione CA; Bonetti A; Campostrini F; Gardani G; Ardizzoia A; Dondi D; Guaraldi M; Cavallo R; Tomio L; Gava A;
Ann Oncol; 2010 Jul; 21(7):1515-1522. PubMed ID: 20032123
[TBL] [Abstract][Full Text] [Related]
16. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
18. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Casanova M; Özyar E; Patte C; Orbach D; Ferrari A; Veyrat-Follet C; Errihani H; Pan J; Zhang L; Shen L; Grzegorzewski KJ; Varan A
Cancer Chemother Pharmacol; 2016 Feb; 77(2):289-98. PubMed ID: 26666649
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Hitt R; Grau JJ; López-Pousa A; Berrocal A; García-Girón C; Irigoyen A; Sastre J; Martínez-Trufero J; Brandariz Castelo JA; Verger E; Cruz-Hernández JJ;
Ann Oncol; 2014 Jan; 25(1):216-25. PubMed ID: 24256848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
